Rhofade Available for Persistent Redness with Rosacea

The FDA approval was based on data from 2 identical, multicentered, randomized, double-blind, and parallel-group trials
The FDA approval was based on data from 2 identical, multicentered, randomized, double-blind, and parallel-group trials

Allergan announced the launch of Rhofade (oxymetazoline HCl) cream 1% for the treatment of persistent facial erythema associated with rosacea in adults.

Rhofade, a once-daily topical cream, was initially approved by the Food and Drug Administration (FDA) in January 2017. Oxymetazoline is an alpha-1A adrenorceptor agonist that acts as a vasoconstrictor. The FDA approval of  Rhofade was based on data from two identical, multicentered, randomized, double-blind, parallel-group, and vehicle-controlled trials in moderate or severe patients (n=885). 

Related Articles

Rhofade applied once-daily demonstrated a reduction in persistent facial erythema associated with rosacea through 12 hours in both clinical trials. It also demonstrated greater efficacy vs. vehicle in reducing persistent facial erythema associated with rosacea in adults.

Rhofade is available as a 1% cream in 30g tubes.

For more information call (800) 433-8871 or visit Rhofade.com.